Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
TOKYOTakeda Global HQ
GREATERBOSTONAREAGlobal Hub
GLOBAL REVENUE
* Pro-forma Apri l 2018-March 2019 combined revenue L-Takeda and L-Shire, converted at Apri l 2018-March 2019 average exchange rate (US $ = 111 yen)
A Global, Values-based, R&D-driven Biopharmaceutical Leader
3RESEARCHSITES
36MANUFACTURINGSITES
30+TOP EMPLOYER® IN
COUNTRIES& REGIONSA S O F F E B R U A R Y 2 0 2 0
13%EMERGING
MARKETS APPROX.
30BN USD*
19%EUROPE &
CANADA 18%JAPAN
50%U.S.
EMPLOYEES
20%EMERGING
MARKETS
31%EUROPE &
CANADA13%JAPAN
36%U.S.
2
APPROX.
50,000EMPLOYEES
80PRESENCE: APPROX. IN
COUNTRIESA S O F F E B R U A R Y 2 0 2 0 1.6
CAPITAL: APPROX.
TRILLION YENA S O F M A R C H 2 0 1 9
As of December 31, 2019A S O F D E C E M B E R 2 0 1 9
01HERITAGE
Takeda was founded in Doshomachi, Osaka, which became the heart of the Japanese medicine industry during the Edo period. Many pharmaceutical companies continue to have their headquarters in this area, leading it to be known as the “medicine town.”
“Work with integrity and deal with medicine as though the patients
being treated were your own children”
We serve the needs of our patients, wherever they are. We earn the trust of society and customers through Takeda-ism. We are recognized as best in class because of agility and innovation, qualities that help us build a steady pipeline and deliver growth, year on year.year.
Corporate Philosophy
Our Mission is to strive towards Better Health and a Brighter Future for people worldwide through leading innovation in medicine.
We take action and make decisions by on our four priorities, in order of:
5
OUR PRIORITIES
VALUES TAKEDA-ISM
1Putting the patient at the center
2Building trust with society
3Reinforcing our reputation
4Developing the business
Since our founding in 1781, our integrity-centered values have guided us in everything we do. They have been inherited as Takeda-ism, with patients as our priority. Takeda-ism continues to guide us in our pursuit of better health for people worldwide.
VISION
MISSION
FOR
SO
CIE
TY
FOR
BU
SIN
ES
S
Our History 1781 - 1979
1781COMPANY FOUNDEDChobei Takeda I sets up his business in Osaka
1915OSAKA FACTORYOpens as “Takeda Pharmaceutical Manufacturing Plant”
1895PRODUCTIONPharmaceutical manufacturing begins in Takeda’s factory
1871INTERNATIONAL TRADETakeda pioneers in the importation of western medicines
1914PROPRIETARY RESEARCHactivities begin
1943COMPANY NAMEbecomes "Takeda Pharmaceutical Company Limited"
1949INITIAL PUBLIC OFFERING Takeda listed on the stock market
1951INTERNATIONAL BUSINESSStarts with North and Central America and Asia
1940“NORI” PRINCIPLESwhich underpin Takeda-ism, are established
1950sPANVITAN® & ALINAMIN® Japan’s first multivitamin product and a Vitamin B1 derivative launch
1961COMPANY LOGOThe current “Dakiyama” logois created
1963TAKEDA SCIENCE FOUNDATIONis established to encourage promising research and science technology
1960SHOSHISHA FOUNDATIONis established to support talented students who will contribute to society
1933TAKEDA GARDENFor Medicinal Plant Conservation opens
6
1946HIKARI FACTORYOpens in Yamaguchi prefecture
FOR
SO
CIE
TY
FOR
BU
SIN
ES
S
Our History 1980 - Present
1980s & 90sEXPANSION OF INTERNATIONAL BUSINESSaccelerates with the launch of leuprorelin, lansoprazole, candesartan, pioglitazone
2011NYCOMED AQUISITIONexpands Takeda’s global footprint into more than 70 countries worldwide
2019TAKEDA INITIATIVE 2 launched to improve maternal and child health by integrating quality HIV, TB, and malaria services in Africa
2009Takeda joins the UNITED NATIONS GLOBAL COMPACT
2008MILLENNIUM PHARMACEUTICALSacquisition enhances innovation in oncology
2019SHIRE ACQUISITIONmakes Takeda a global biopharmaceutical leader with a presence in approximately 80 countries
2010TAKEDA INITIATIVEis formed to support the development of healthcare professionals in Africa
2016ACCESS TO MEDICINESprogram launched to improve access to care and treatment for patients in underserved communities
GLOBAL CSR PROGRAM launched to contribute to the better health of people through disease prevention.
2018NEW YORK STOCK EXCHANGE LISTINGThe only pharmaceutical company listed on both the TSE and the NYSE
SHONAN HEALTH INNOVATION PARKopens as the first pharma-led open innovation ecosystem in Japan
TAKEDA GLOBAL HEADQUARTERS opens in Tokyo, providing an environment that supports diverse workstyles
7
02DIVERSITY
Diverse perspectives lead to insightful solutions
Our employees are the cornerstone of our success. Diverse workplaces where all employees are welcomed and empowered inspire them and enable health innovation that meets the needs of patients, customers and communities.
Takeda Executive Team (TET)SW
ITZE
RLA
ND
SIN
GA
PORE
R ICARDO MARE KPresident, Growth & Emerging Markets Business Unit
GILE S PLATFO RDPresident, Europe & Canada Business Unit
THO MAS WO ZNIE WSKIGlobal Manufacturing & Supply Officer
J ULIE K IM President, Plasma-Derived Therapies Business Unit
CAMILLA SO E NDE RBYChief Patient Value & Product Strategy Officer
MWANA LUGO GOChief Ethics & Compliance Officer
U.S
.
ANDY PLUMPPresident, Research & Development
RAMO NA SE QUE IRA President, U.S. Business Unit and Global Portfolio Commercialization
TE RE SA BITE TTIPresident, Global Oncology Business Unit
RAJ E E V VE NKAYYAPresident, GlobalVaccine Business Unit
GE RARD ( J E RRY) GRE COGlobal Quality Officer
MARCE LLO AGO STIGlobal Business Development Officer
JAPA
N
CHRISTO PHE WE BE RPresident & CEO
MASATO IWASAKIPresident, Japan Pharma Business Unit
COSTA SAROUKOSChief Financial Officer
YO SHIHIRO NAKAGAWAGlobal General Counsel
MILANO FURUTACorporate Strategy Officer & Chief of Staff
PADMATHIRUVE NGADAMChief Human Resources Officer
TAKAKO O HYABUCorporate Communications & Public Affairs Officer
9
The gender, age and geographic diversity of the Takeda Executive Team together with its functional expertise and unparalleled experience, ensures quick and transparent decision-making
Board of Directors
SHIRO KUNIYAIndependent Director
KO J I HATSUKAWAIndependent Director,Chair of A&SC
MASAHIRO SAKANEIndependent DirectorChair of the Board meetingChair of Nomination Committee
CB
NC
COMPENSATION COMMITTEE
NOMINATION COMMITTEE2
INDEPENDENT DIRECTOR
CHAIR OF THE BOARD MEETING
NC
CB
CC
YO SHIAKI FUJ IMO RIIndependent Director
CC
INDEPENDENT DIRECTORS1
IAN CLARKIndependent Director
CC
E MIKO HIGASHIIndependent DirectorA&SC memberChair of Compensation Committee
CC
STE VE N GILL ISIndependent Director
NC
TO SHIYUKI SHIGAIndependent Director
NC
OLIVIE R BOHUONIndependent Director
CC
J E AN- LUC BUTE LIndependent Director
NC
MICHE L O RSINGE RIndependent DirectorA&SC Member
NC
AUDIT & SUPERVISORY COMMITTEE (A&SC)
CHRISTO PHE WE BE RRepresentative Director,President & CEO
ANDRE W PLUMPDirector, President, Research & Development
YASUHIKO YAMANAKADirector,A&SC member
MASATO IWASAKIDirector, President, Japan Pharma Business Unit
INTERNAL DIRECTORS
COSTA SAROUKOSDirector,Chief Financial Officer
101. As defined by Tokyo Stock Exchange l i st ing rules2. Chr istophe Weber partic ipates in the committee as an observer
Takeda cherishes best-in-class governance. Takeda’s board is comprised of 16 experienced global leaders from diverse backgrounds. Eleven of them are independent external directors.
Corporate Governance Diagram
11
Our advanced and robust corporate governance model has been and will continue to be, critical to our success.
TAKE DA E XE CUTIVE TE AM (TE T)
R E P O R T ING
C O NS U L T A T IO N
RECOMMENDATION
A P P O INT M E NT /DIS M IS S A L /NO N- R E A P P O INT M E NTO F M E M B E R S
NO MINATIO N CO MMITTE E
CO MPE NSATIO N CO MMITTE E
ACCO UNTING AUDITO RAUDIT AND SUPE RVISO RY CO MMITTE E
THE GRO UP INTE RNAL AUDIT DE PARTME NT
A U DIT ING
R E P O R T ING INS T R U C T IO N
R E P O R T ING / S T A T E M E NTO F O P INIO N
A P P O INT M E NT/ D IS M IS S A LO F M E M B E R S
R E P O R T INGR E P O R T ING
HE AD O F E ACH UNIT AND PRE SIDE NTS O F THE GRO UP CO MPANIE S
R E P O R T ING
DIS C U S S IO N/R E P O R T ING S U P E R V IS IO N
PRE SIDE NT AND CHIE F E XE CUTIVE O FFICE (CE O )
PORTFOLIO RE VIE W CO MMITTE E
BUSINE SS RE VIE W CO MMITTE E
RISK, E THICS &CO MPLIANCE CO MMITTE E
A P P O INT M E NT/ D IS M IS S A L
R E P O R T ING INS T R U C T IO N
DIS C U S S IO N/R E P O R T ING
E X E C U T IO N- R E L A T E D INS T R U C T IO NS / S U P E R V IS IO N
INT E R NA L A U DIT ING
GE NE RAL ME E TING O F SHARE HO LDE RS
LE ARN MO RE O N TAKE DA.CO M
BOARD OFDIRE CTO RS
CH AIRINDE PE NDE NT DIRE CTO R
A P P O INT M E NT /DIS M IS S A L /NO N-R E A P P O INT M E NTO F M E M B E R S
Growth & Emerging Markets Business UnitPresident
U.S. Business UnitPresident, and President of Global Portfolio Commercialization
Japan Pharma Business UnitPresident
Europe & Canada Business UnitPresident
Global Oncology Business UnitPresident
Plasma-Derived TherapiesBusiness Unit President
Global Vaccine Business UnitPresident
Patient Value and Product Strategy Chief PVPS Officer
Research & DevelopmentPresident
Global Manufacturing and Supply GMS Officer
Global Quality Global Quality Officer
RE GIO NAL BUs BUSINE SS FUNCTIO NS
BUSINE SS PARTNE RS
RICARDO MAREK
RAMONA SEQUEIRA MASATO IWASAKI
GILES PLATFORD
TERESA BITETTI JULIE KIM
RAJEEV VENKAYYA CAMILLA SOENDERBY
ANDY PLUMP THOMAS WOZNIEWSKI
GERARD (JERRY) GRECO
Global Organization Chart
Global FinanceChief Financial Officer
COSTA SAROUKOS
Global Human Resources Chief Human Resources Officer
PADMA THIRUVENGADAM
Global General Counsel
YOSHIHIRO NAKAGAWA
Global Ethics & Compliance Chief Ethics & Compliance Officer
MWANA LUGOGO
Global Business Development Global Business Development Officer
MARCELLO AGOSTI
Corporate StrategyCorporate StrategyOfficer &Chief of Staff
MILANO FURUTA
GLO BAL SPE CIALTY BUs
Corporate Communications and Public AffairsCCPA Officer
SHARE HO LDE RS' ME E TING
BOARD OF DIRE CTORS (BOD)AUDIT AND
SUPE RVISO RYCO MMITTE E
GRO UP INTE RNAL AUDIT
ASC O FFICE
President & CEO President & Chief Executive Officer
CHRISTOPHE WEBER
NO MINATIO NCO MMITTE E
CO MPE NSATIO NCO MMITTE E
12
TAKAKO OHYABU
Our agile and simple organization empowers local leaders to make decisions and act in the best interests of our patients.
High potential talent development moving globally and across business/functions
TAKE DA LE ADE RSHIPBE HAVIO RS
A new set of expectations for transformational leadership
Talent Development
LE ADE RSHIP AT TAKE DA BRINGS A NE W SE T O F E XPE CTATIO NS FO R TRANSFO RMATIO NAL LE ADE RSHIP
ACCE LE RATO R PRO GRAM
International cross-functional development for high-potential employees early in their careers
GLO BAL TALE NT PO O L
Induction training for recently-hired senior leaders
GLO BAL INDUCTIO N FO RUM
Takeda’s executive management team personally nurture talented people to lead the company in the future
PRE SIDE NT’S FO RUM
E NTE RPRISE LE ADE RS
ACCE LE RATO RS
GLO BAL PRO GRAMS
TET
TRANSFO RMATIO N LE ADE RS
MID- CARE E R FUTURE LE ADE RS
E ARLY CARE E R HIGH- PO TE NTIALS
TAKE DA E XE CUTIVE TE AM
13
Our employees are the cornerstone of our success.
Our significant investment in training offers everyone the opportunity to work at the highest levels of our industry, with fast-track programs accelerating the progress of high-potential candidates.
03INNOVATION
How our R&D translate science into highly innovative,
life-changing medicines
Innovation is at the heart of our R&D. Our researchers and scientists are striving to bring scientific breakthroughs from the lab to patients worldwide.
We are a patient-driven, science first R&D organization. We combine our focus on core therapeutic areas with cutting-edge technologies.
15
VACCINESPLASMA-DERIVEDTHERAPIES
ONCOLOGY RARE DISEASES NEUROSCIENCE GASTRO-ENTEROLOGY
Our R&D Focus
Innovative Biopharma
LEARN MORE ABOUT OUR PIPELINE ON TAKEDA.COM
DIVERSIFIED MODALITIES IN RESEARCH
ACTIVE PARTNERSHIPS ROBUST CLINICAL PIPELINE OF NOVEL
MECHANISMS
16
70%
We leverage our own internal research capabilities, while also actively engaging with innovative ecosystems around the world to translate science into highly transformative or curative potential medicines for targeted populations with a high unmet need.
R&D INVESTMENT
$4.5bnPER YEAR
200• Biologics• Cell & Gene
Therapies• Microbiome &
Other Modalities• Peptides &
Oligonucleotides
• Small Molecules
APPROX.
50%Pipeline with orphan drug designation*
Our Internal R&D Engine and External Collaborations
40New molecular entity clinical stage assets
APPROX.
Approx.
Approx.
OVER
*31 Orphan Drug Designations in at least one indication for assets in Phase 1 through LCM in 2019 versus 15 in 2018
Our balanced business portfolio which is composed of life-transforming, highly innovative medicines in our key business areas, drives our growth.
17
21%OTHERS
13%NEURO-SCIENCE
13%ONCOLOGY
12%PLASMA-DERIVEDTHERAPY
20%RARE
DISEASES
21%GASTRO-
ENTEROLOGY
PERCENTAGE OF SALES*
5 KEY BUSINESS AREAS
14 STRATEGIC GLOBAL BRANDS
80% OF REVENUE
CORE BUSINESS APPROX.
* Percentage of sa les refers to Apr i l 2019 – December 2019 revenue.
Business Portfolio
04SUSTAINABILITY
Corporate Governance Scorecard
Our long-term commitment along with Sustainable
Development Goals (SDGs)Our employees worldwide decide which activities and partners our Global CSR program supports. Selected employees visit sites supported by those partners through our Employee Participation Program.
Environmental Reduction GoalsAchievements by the end of FY2018
1. Sul fur Oxides (SO X) and Nitrogen Oxides (NO X) resul t ing from var ious on-s i te combustion processes2. Performance against goals excludes contr ibution from Shire acquis i t ion
19
Takeda is committed to ambitious action to prevent and mitigate the effects of a changing climate and has set a goal of becoming a carbon neutral organization, inclusive of all greenhouse gas emissions throughout our value chain by 2040.
19
GOAL FOR 2020 (BASELINE 2005)
AS OF END FY2018
CO2 25% 33.7%
NOX 20% 59%
SOX 75% 99.1%
FRESH WATER USE 30% 48%
WASTE TO LANDFILL 60% 68.3%JAPAN ONLYONLY
TARGET
LE ARN MO RE ABO UT O UR CO MMITME NT TO CARBO N NE UTRALITY O N TAKE DA.CO M
Our Global CSR Program & Partnerships play a vital role in disease prevention and strengthening health care systems through long-term commitments in developing and emerging countries.
Strategic Engagement for Sustainability
Programs selected by employee votes each year
Total amount donated from FY2016-2019
¥10.5Bn
20
GLOBAL CSR PARTNERSHIPS:WORKING TOGETHER WITH GAME-CHANGING MULTILATERAL AND
ACADEMIC INSTITUTIONS WORLDWIDE
LE ARN MO RE ABO UT O UR PRO GRAMS O N TAKE DA.CO M
14Global CSR Programs
GLOBAL CSR PROGRAM ©City Cancer Challenge
©DNDi/Fabio Nascimento
©UNICEF/UN0265456/Chute
Improving Access to Medicines for patients worldwide
In 2016 we launched a new Access to Medicines strategy focused on geographies and therapeutic areas with high unmet medical needs to tackle the many barriers that prevent patients from accessing the care and treatment they need for complex and rare diseases.
Our approach to improving access is sustainable and targeted, to strengthen and transform healthcare systems, at every stage of the patient journey - from awareness and diagnosis, to treatment and ongoing patient support.
Supported more than 125,000 patients with treatment they need
Supported healthcare providers in screening over 1.1 million patients for cancer, hypertension and diabetes
Trained over 4,000 healthcare providers and community health workers to provide improved patient care
Implemented patient-focused access programs in 52 countries and territories
In 2018 the Access to Medicine Index recognized our strategy and the progress we are making in improving access, with Takeda climbing 10 places to rank number five
21LE ARN MO RE ABO UT O UR ACCE SS TO ME DICINE S STRATE GY O N TAKE DA.CO M
Visit us online atwww.takeda.com
IMPORTANT NOTE This Corporate Overview contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider. PANVITAN® and ALINAMIN® are either registered trademarks or trademarks of Takeda Pharmaceutical Company Limited and/or its affiliates in Japan and/or other countries.
TAKEDA GLOBAL HEADQUARTERSCreative Director Kashiwa Sato selected people’s “life force” as the overall concept for the interior design, which is expressed through a series of eight Japanese characters, as instillation art throughout the building.
Published: April 2020Corporate Communications and Public Affairs